Literature DB >> 1320544

Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.

R Zietse1, G J Wenting, P Kramer, M A Schalekamp, W Weimar.   

Abstract

1. To elucidate the mechanisms by which cyclosporin A diminishes proteinuria, we studied 20 patients with severe nephrotic syndrome. Biopsy-established pathologies included minimal change disease (n = 5), membranous glomerulopathy (n = 6), membranoproliferative glomerulonephritis (n = 5) and focal segmental glomerulosclerosis (n = 4). Before, at the end of a 90 day course of cyclosporin A, and finally 1 month after stopping cyclosporin A we determined 24 h protein excretion. Measurements of glomerular filtration rate, effective renal plasma flow, fractional clearance rates of albumin and immunoglobulins with different charges and the transglomerular sieving of uncharged dextrans of broad size distribution were used to study the effects of cyclosporin A on renal perfusion and the glomerular filtration barrier. The findings were analysed with a theoretical model of solute transport. 2. Among the different forms of glomerulopathy the response to low-dose cyclosporin A (trough levels 32.0-36.9 ng/ml) varied markedly. In minimal change disease, proteinuria decreased from 9.5 +/- 3.1 to 1.3 +/- 0.2 g/24 h (mean +/- SEM, P less than 0.01). This response was due to restoration of the charge selectivity of the glomerular barrier. The depressed value of the glomerular permeability coefficient also returned to normal. Glomerular filtration rate, effective renal plasma flow and renal vascular resistance did not change. Proteinuria returned after stopping cyclosporin A, although it did not reach pretreatment levels. In membranous glomerulopathy, proteinuria fell from 9.9 +/- 1.5 to 1.8 +/- 0.3 g/24 h (P less than 0.01). Changes in protein excretion and dextran sieving were compatible with an increase in glomerular permselectivity and a decrease in filtrate flow through the 'shunt' pathway. Glomerular filtration rate was maintained, although effective renal plasma flow fell significantly. Proteinuria relapsed after stopping cyclosporin A. In membranoproliferative glomerulonephritis and focal segmental glomerulosclerosis proteinuria did not respond to cyclosporin A, although cyclosporin A exerted important haemodynamic effects. 3. In minimal change disease and membranous glomerulopathy cyclosporin A exerts its beneficial effects on proteinuria through changes in the properties of the glomerular barrier, resulting in increased charge and size selectivity, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320544     DOI: 10.1042/cs0820641

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  17 in total

Review 1.  Pathogenesis and therapy of focal segmental glomerulosclerosis: an update.

Authors:  Rasheed Gbadegesin; Peter Lavin; John Foreman; Michelle Winn
Journal:  Pediatr Nephrol       Date:  2010-11-26       Impact factor: 3.714

2.  Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.

Authors:  Albert Bensman; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2010-03-02       Impact factor: 3.714

3.  Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.

Authors:  Anja K Büscher; Birgitta Kranz; Rainer Büscher; Friedhelm Hildebrandt; Bernd Dworniczak; Petra Pennekamp; Eberhard Kuwertz-Bröking; Anne-Margret Wingen; Ulrike John; Markus Kemper; Leo Monnens; Peter F Hoyer; Stefanie Weber; Martin Konrad
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

4.  Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience.

Authors:  M P Delaney; D C Dukes; M E Edmunds
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

5.  Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy.

Authors:  Jae Il Shin; Beom Jin Lim; Pyung Kil Kim; Jae Seung Lee; Hyeon Joo Jeong; Ji Hong Kim
Journal:  J Korean Med Sci       Date:  2010-04-22       Impact factor: 2.153

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Focal segmental glomerulosclerosis complicating solitary kidney.

Authors:  Yoshiyuki Oshiro; Sachio Umena; Masatoshi Noda
Journal:  Clin Exp Nephrol       Date:  2008-08-09       Impact factor: 2.801

8.  Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome.

Authors:  S A Hulton; L Jadresic; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

9.  Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS.

Authors:  Lawrence Copelovitch; Marta Guttenberg; Martin R Pollak; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2007-05-25       Impact factor: 3.714

10.  Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.

Authors:  Beom Seok Kim; Hyeong Cheon Park; Shin Wook Kang; Kyu Hun Choi; Sung Kyu Ha; Dae Suk Han; Ho Yung Lee
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.